%0 Journal Article
%T Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received
%A Davide Motta
%A Nigritella Brianese
%A Emanuele Foc¨¤
%A Paola Nasta
%A Franco Maggiolo
%A Massimiliano Fabbiani
%A Giuliana Cologni
%A Simona Di Giambenedetto
%A Massimo Di Pietro
%A Nicoletta Ladisa
%A Laura Sighinolfi
%A Silvia Costarelli
%A Filippo Castelnuovo
%A Carlo Torti
%J AIDS Research and Therapy
%D 2012
%I BioMed Central
%R 10.1186/1742-6405-9-18
%X We performed a longitudinal analysis of 3,262 patients from the MASTER cohort, who started HAART from 2000 to 2008. Patients were stratified into 6 groups by HCV status and type of anchor class. The early virological outcome was the achievement of HIV RNA <500 copies/ml 4¨C8£¿months after HAART initiation. Time to virological response was also evaluated by Kaplan-Meier analysis. The main outcome measure of early immunological response was the achievement of CD4+ T-cell increase by ¡İ100/mm3 from baseline to month 4¨C8 in virological responder patients. Late immunological outcome was absolute variation of CD4+ T-cell count with respect to baseline up to month 24. Multivariable analysis (ANCOVA) investigated predictors for this outcome.The early virological response was higher in HCV Ab-negative than HCV Ab-positive patients prescribed PI/r (92.2% versus 88%; p£¿=£¿0.01) or NNRTI (88.5% versus 84.7%; p£¿=£¿0.06). HCV Ab-positive serostatus was a significant predictor of a delayed virological suppression independently from other variables, including types of anchor class. Reactivity for HCV antibodies was associated with a lower probability of obtaining ¡İ100/mm3 CD4+ increase within 8£¿months from HAART initiation in patients treated with PI/r (62.2% among HCV Ab-positive patients versus 70.9% among HCV Ab-negative patients; p£¿=£¿0.003) and NNRTI (63.7% versus 74.7%; p£¿<£¿0.001). Regarding late CD4+ increase, positive HCV Ab appeared to impair immune reconstitution in terms of absolute CD4+ T-cell count increase both in patients treated with PI/r (p£¿=£¿0.013) and in those treated with NNRTI (p£¿=£¿0.002). This was confirmed at a multivariable analysis up to 12£¿months of follow-up.In this large cohort, HCV Ab reactivity was associated with an inferior virological outcome and an independent association between HCV Ab-positivity and smaller CD4+ increase was evident up to 12£¿months of follow-up. Although the difference in CD4+ T-cell count was modest, a stricter follow-up and optimizat
%K HIV
%K HCV
%K HAART
%U http://www.aidsrestherapy.com/content/9/1/18/abstract